



www.galienfoundation.org

GALIEN AWARDS COMMITTEE - USA 2016

PR RICHARD AXEL, M.D.

Nobel Laureate, Co-director, the Kavli Institute for Brain Science, Columbia University Medical Center, New York

PR MICHAEL S. BROWN, M.D.

Nobel Laureate, Professor of Molecular Genetics and Internal Medicine, UT, Southwestern Medical Center, Dallas, TX

PR LAURIE GLIMCHER, M.D.

Chief Executive Officer and President, Dana Farber Cancer Institute, Professor of Medicine, Harvard Medical School

PR JOSEPH GOLDSTEIN, M.D.

Nobel Laureate, Professor of Molecular Genetics and Internal Medicine, UT, Southwestern Medical Center, Dallas, TX

PR ROBERT S. LANGER, M.D.

David H. Koch Institute Professor, MIT

PR PAUL A. MARKS, M.D.

Laboratory Head of Cell Biology, Memorial Sloan Kettering Cancer Center, New York President, Emeritus, MSKCC

PR BENGT SAMUELSSON, M.D., PH.D.

Nobel Laureate, Former President of Karolinska Institute and Former Chairman of the Nobel Foundation

PR MARC TESSIER-LAVIGNE, PH.D. President, Stanford University, Stanford, CA

PR ROY VAGELOS, M.D., Committee Chairman Chairman of Regeneron Pharmaceuticals, Retired Chairman and Chief Executive Officer, Merck & Co., Inc.

The GALIEN FOUNDATION

FLIE WIESEL®

Ferce Nobel Laureate, Boston University Founding Honorary President

* in Memoriam

THE GALIEN FOUNDATION MISSION

The Prix Galien is more than an award: it is a movement with a mandate to foster, recognize and reward excellence in scientific innovation to improve the state of human health. Building on an unrivaled network of Nobel Laureates in medicine, the Prix Galien manages an independent, cross-functional and geographically diverse program of events and sponsorships to brand "the best of the best" in new medicines and diagnostics.

Our scope is global, and our commitment to progress in medicine is both measurable and concrete. Our members express this through the establishment of productive relationships to build lasting bridges between the commercial research enterprise and local communities engaged in public policy, science, finance, academic research and the media.

In addition to recognizing advances in promising therapies, the Prix Galien's annual Pro Bono Humanum Award for humanitarian achievements brings a unique focus to the intersection between science, business and politics. The outcome we seek is guided by the synthesis principle that underpins the conduct of science itself: successful innovation where financing, physical assets, knowledge and skills are combined from many sources to move new ideas quickly "from the bench to the bedside," on behalf of patients everywhere.

A truly global program present in 14 countries*

Our program includes a review of contributions from a new generation of innovators representing diverse sectors in health as well as from the emerging markets of the developing world. Our theme: better cross-cultural contacts, harmonized regulation, internal business process improvements, new information technologies and effective public-private partnerships can remove barriers to the commercialization of good medicines and expand access to these benefits to all who need them.

2016 will represent a new and exciting stage in the evolution of the Prix Galien as the pre-eminent "force populaire" behind the global scientific enterprise. With the support of our sponsoring organizations, our efforts will extend to all who see medical innovation not only as an industrial policy asset but as a source of social progress - where private enterprise and public engagement combine to deliver a greater public good.

We invite all communities with a commitment to the conduct and promotion of life sciences innovation to contribute to this important work.

* Belgium, Canada, France, Germany, Greece, Italy, Netherlands, Poland, Portugal, Russia, Spain, Switzerland, United Kingdom and the United States.

SAVE THE DATE PRIX GALIEN USA NEW YORK CITY OCTOBER 26, 2017

The Prix Galien Award recognizes outstanding achievements in improving the global human condition through the development of innovative drugs and other treatments.

The Prix Galien was created in 1970 in honor of Galen, the father of medical science and modern pharmacology.

Worldwide the Prix Galien is regarded as the equivalent of the Nobel Prize in biopharmaceutical research.




INNOVATION TO IMPROVE THE HUMAN CONDITION

Pr Roy VAGELOS during the campaign against river blindness in West Africa.

SCIENTIFIC AMERICAN

VOLUME 316, NUMBER 1

JANUARY 2017



PREDITOS CTENCT

26 Lab-Built Brains

Scientists copy nature's most complex organ in the hope of solving the mysteries of brain disorders, from autism to Alzheimer's. By Juergen A. Knoblich

SPACE

32 Tangled Up in Spacetime

The collaborative project "It from Qubit" is investigating whether space and time sprang from the quantum entanglement of tiny bits of information. By Clara Moskowitz

CARDIOLOGY

38 Heart Therapy

Harnessing the organ's own healing properties may help prevent heart attacks and lessen the painful effects of severely narrowed coronary arteries. By Gabor Rubanyi

COMPUTING

44 The Case for Robot Disobedience

Don't worry about defiant machines. Devious human masters are a bigger threat. By Gordon Briggs and Matthias Scheutz

EVOLUTION

48 Taking Wing

Remarkable fossils trace the rise of birds from dinosaurs. By Stephen Brusatte

CRIMINAL JUSTICE

56 Animal CSI

Veterinary forensic science is helping prosecutors convict people who abuse animals. By Jason Byrd and Natasha Whitling

Q&A

64 Wildlife Warrior

Paleontologist-turned-politician Richard Leakey leads the charge in Kenya's war on poaching. By Richard Schiffman



ON THE COVER

New tools allow neuroscientists to grow parts of a brain in a lab dish. These "organoids" model the human brain more realistically than mice or other animals do. Brains-in-a-dish have already been put to good use to understand the Zika virus, Image by Bryan Christie.

SCIENTIFIC AMERICAN







3 From the Editor

4 Letters

7 Science Agenda

Presidential elections have a way of rearranging NASA's goals. By the Editors

o Forum

Armed security guards in hospitals do more harm than good. By Nathaniel P. Morris

10 Advances

Some monkeys create "tools" that look suspiciously like those of early humans. STDs on the rise. A huge telescope from miniature satellites. Hidden side effects.

22 The Science of Health

Is supercooling the entire body therapeutic? By Dina Fine Maron

24 TechnoFiles

E-mail will never be secure. By David Pogue

68 Recommended

Historic brain drawings. Physics in everyday life. The Anthropocene epoch is now. By Clara Moskowitz

69 Skeptic

Why deeply held beliefs get stronger in the face of overwhelming contrary evidence. By Michael Shermer

70 Anti Gravity

Baseball's acceptance of analytics is a lesson for other fields. By Steve Mirsky

71 50, 100 & 150 Years Ago

72 Graphic Science

The top air polluters in the U.S. By Mark Fischetti

ON THE WEB

Breakthrough Prize

Scientific American spotlights the 2017 winners' outstanding scientific achievements.

Go to www.ScientificAmerican.com/jan2017/breakthrough

Scientific American (ISSN 0036-8733). Volume 316. Number 1, January 2017, published monthly by Scientific American, a division of Nature America, Inc., 1 New York, Plaza, Suite 4500, New York, N.Y. 10004-1562. Periodicals postage paid at New York, N.Y., and at additional mailing offices. Canada Post International Publications Mail (Canadian Distribution) Sales Agreement No. 40012504. Canadian BN No. 127387652RT; TVQ1218059275 TQ0001. Publication Mail Agreement #40012504. Return underverable mail to Scientific American, P.O. Box 819, Stin Main, Markham, ON L3P 8A2. Individual Subscription rates: 1 year \$49.99 (USD), Canada \$59.99 (USD), International Subscription rates: 1 year \$49.99 (USD), Canada \$59.99 (USD), International \$69.99 (USD), Businesses and Colleges/Universities: 1 year \$49.99 (USD), Canada \$405 (USD), International \$411 (USD) (USD), East Canada Subscription rates: 1 year \$49.99 (USD), Canada \$405 (USD), International \$411 (USD) (USD), Canada Subscription rates: 1 year \$40.00 (USD), Canada \$405 (USD), International \$411 (USD) (USD), Canada Subscription rates: 1 year \$40.00 (USD), Canada Subscription rates: 1 year \$40.00 (USD), Canada \$405 (USD), International \$411 (USD) (USD), Canada Subscription rates: 1 year \$40.00 (USD), Canada Subscription ra

Scientific American is part of Springer Nature, which owns or has commercial relations with thousands of scientific publications (many of them can be found at www.springernature.com/us). Scientific American maintains a strict policy of editorial independence in reporting developments in science to our readers. Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Mariette DiChristina is editor in chief of Scientific American. Follow her on Twitter @mdichristina.

What's Next for Science?

Wednesday, November 9, dawned gray and raw in Berlin. I was there to moderate a couple of panels at an annual meeting called Falling Walls. The name and timing celebrate the anniversary of the Berlin Wall's fall, as well as the free exchange of ideas if only we can knock down barriers. I looked forward to a series of inspiring talks about how science, which I have often called the "engine of human prosperity," could help us solve some of our greatest challenges.

We all crowded into a large room at the start of the day. A live broadcast began, looming above us on an enormous screen. The Falling Walls attendees watched the accep-

tance speech of the U.S. president-elect, Donald Trump, whose campaign included a promise to build a new wall.

What would this mean for science, I wondered? As a candidate, Trump had made some troubling antiscience statements, including tweeting that global climate change is a Chinese plot, threatening that he would dismantle the agency that enforces clean air and water regulations, and endorsing the long-disproved link between vaccines and autism. Any hope that he would soften



BERLIN WALL being destroyed in November 1989.

those stances after victory were quickly dashed. His first actions as president-elect included putting forward a climate change skeptic to head the Environmental Protection Agency and reportedly looking to make good on his earlier intent to pull out of the Paris climate accord.

For 171 years, Scientific American has chronicled the advanc-

es of science (and even fostered its application, with its patenting offices, starting in 1850). While at Falling Walls, I reflected on how many voters had come to feel disenfranchised in the face of that progress, leaving them with a sense of reduced opportunity. I thought about how we who work in and around science could be more inclusive in our outreach to them and to policy leaders and how we could help take a systems approach to better ensure that research will be applied in ways that result in greater public benefit. I thought about how we could still work together to build a better world. We just might have to try a little harder to get there.

For these reasons, we are expanding the scope of our reporting on public policies that will affect science to round out our traditional coverage of the impact of that research on human lives.

One thing is as clear today as it was when this magazine was founded in 1845, during the flowering of the industrial revolution in the U.S.: a world in search of solutions to humanity's challenges needs information about science, and Scientific American will be tireless in providing it.

HOARD OF ADVISERS

Leslie C. Aiello President, Wenner-Gren Foundation for Anthropological Research

Roger Bingham

Co-Founder and Director. The Science Network

Arthur Caplan Director, Division of Medical Ethics, Department of Population Health, NYU Langone Medical Center

Vinton Cerf Chief Internet Evangelist, Google

George M. Church Director, Center for Computational Genetics: Harvard Medical School

Rita Colwell Distinguished University Professor University of Maryland College Park

and Johns Hopkins Bloomberg School of Public Health Richard Dawkins

Founder and Roard Chairman. Richard Dawkins Foundation Drew Endy

Professor of Bioengineering. Stanford University

Edward W. Felten Director, Center for Information Technology Policy, Princeton University Kaigham J. Gabriel

President and Chief Executive Officer, Charles Stark Draper Laboratory

Harold "Skip" Garner

Executive Director and Professor. Primary Care Research Network and Center for Bioinformatics and Genetics, Edward Via College of Osteopathic Medicine

Michael S. Gazzaniga

Director, Sage Center for the Study of Mind, University of California. Santa Barbara

David J. Gross

Professor of Physics and Permanent Member, Kavli Institute for Theoretical Physics, University of California, Santa Barbara (Nobel Prize in Physics, 2004)

Lene Vestergaard Hau

Mallinckrodt Professor of Physics and of Applied Physics, Harvard University

Danny Hillis

Co-chairman, Applied Minds, LLC

Daniel M. Kammen

Class of 1935 Distinguished Professor of Energy, Energy and Resources Group. and Director, Renewable and Appropriate Energy Laboratory, University of California, Berkeley

Vinod Khosla

Partner, Khosla Ventures

Christof Koch

President and CSO, Allen Institute for Brain Science

Lawrence M. Krauss

Director, Origins Initiative, Arizona State University

Morten L. Kringelbach

Director, Hedonia: TrygFonden Research Group, University of Oxford and University of Aarhus

Steven Kyle

Professor of Applied Economics and Management, Cornell University

Robert S. Langer

David H. Koch Institute Professor, Department of Chemical Engineering, M.I.T.

Lawrence Lessig Professor, Harvard Law School

John P. Moore

Professor of Microbiology and Immunology, Weill Medical College of Cornell University

M. Granger Morgan

Hamerschlag University Professor Engineering and Public Policy. Carnegie Mellon University

Miguel Nicolelis

Co-director, Center for Neuroengineering, Duke University Martin A. Nowak

Director, Program for Evolutionary Dynamics, and Professor of Biology and of Mathematics, Harvard University

Robert E. Palazzo

Dean, University of Alabama at Birmingham College of Arts and Sciences

Carolyn Porco

Leader, Cassini Imaging Science Team, and Director, CICLOPS, Space Science Institute

Vilayanur S. Ramachandran

Director, Center for Brain and Cognition, University of California, San Diego

Lisa Randall

Professor of Physics. Harvard University

Martin Rees

Astronomer Royal and Professor of Cosmology and Astrophysics, Institute of Astronomy, University of Cambridge

John Reganold

Regents Professor of Soil Science and Agroecology, Washington State University

Jeffrey D. Sachs Director, The Earth Institute. Columbia University

Eugenie C. Scott National Center for Science Education Terry Sejnowski

Professor and Laboratory Head of Computati onal Neurob Laboratory, Salk Institute for Biological Studies

Michael Shermer

Publisher Skeotic massarine

Michael Snyder

Professor of Genetics, Stanford University School of Medicine

Michael E. Webber

Co-director, Clean Energy Incubator, and Associate Professor, Department of Mechanical Engineering, University of Texas at Austin

Steven Weinberg

Director, Theory Research Group, Department of Physics, University of Texas at Aust (Nobel Prize in Physics, 1979)

George M. Whitesides

Professor of Chemistry and Chemical Biology, Harvard University

Nathan Wolfe Director, Global Viral Forecasting

Initiative

Anton Zeilinger Professor of Quantum Optics, Quantum Nanophysics, Quantum Information, University of Vienna

Jonathan Zittrain

Professor of Law and of Computer Science, Harvard University